New brain scans could sharpen diagnosis of lewy body dementia
NCT ID NCT00917709
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study used special brain scans (SPECT imaging) to look at two key brain chemicals—acetylcholine and dopamine—in people with dementia with Lewy bodies. Researchers aimed to see if differences in these chemicals could help diagnose the disease and identify subtypes. The study included 34 participants and was completed, but it was an observational imaging study, not a treatment trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better diagnose dementia with Lewy bodies and identify different types of the disease.
- What could go wrong
- This was a small, early-stage imaging study with only 34 participants, so results may not apply to everyone. It did not test a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA WITH LEWY BODIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Groupe Hospitalier Pellegrin - C.H.U. de Bordeaux
Bordeaux, 33076, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Skin, speech, and brain scans may unmask hidden neurodegeneration
- Can sound waves soothe Dementia's emotional turmoil?
- Cancer drug shows promise for treating lewy body dementia
- Could tiny doses of radiation slow Alzheimer's? a new trial investigates
- Brain scans track Alzheimer's clues over decades
- Can a One-Time bone drug shield Parkinson's patients from fractures?